<DOC>
	<DOC>NCT00752986</DOC>
	<brief_summary>The primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..</brief_summary>
	<brief_title>ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial</brief_title>
	<detailed_description>end-point Efficacy: event-free survival (EFS)</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Post menopausal women with locally advanced or metastatic breast cancer Patients may have either measurable or nonmeasurable disease, as defined by RECIST criteria One previous hormone therapy or one previous chemotherapy for advanced disease are allowed (patients who have stable but evident disease after chemotherapy are eligible) estrogen receptor positive ER+ and/or progesterone receptor positive PR+ on primary or secondary tumour Hormone receptor negative tumours (ER and PR negative) Presence of lifethreatening metastatic visceral disease Significant cardiovascular event (e.g. myocardial infarction, superior vena cava [SVC] syndrome, New York Heart Association [NYHA] classification of heart disease ³2) within 3 months before entry, or presence of cardiac disease that in the opinion of History of arrhythmia or QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ZD6474</keyword>
	<keyword>Vandetanib</keyword>
	<keyword>Zactima</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Faslodex</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Advanced, Metastatic</keyword>
	<keyword>Hormone Receptor Positive</keyword>
	<keyword>Post-Menopausal Patients</keyword>
	<keyword>post-menopausal women with hormone receptor positive advanced breast cancer</keyword>
</DOC>